scholarly journals The Distribution and Outcomes of the 21-Gene Recurrence Score in T1-T2N0 Estrogen Receptor-Positive Breast Cancer With Different Histologic Subtypes

2018 ◽  
Vol 9 ◽  
Author(s):  
Jun Wang ◽  
Zhen-Yu He ◽  
Yong Dong ◽  
Jia-Yuan Sun ◽  
Wen-Wen Zhang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Recurrence Score ◽  
Estrogen Receptor Positive ◽  
Histologic Subtypes ◽  
Positive Breast Cancer

Cost-effectiveness of the 21-gene recurrence score assay in the setting of multifactorial decision making for chemotherapy in early-stage breast cancer.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 1525-1525
Author(s):  
Shelby D. Reed ◽  
Michaela A Dinan ◽  
Kevin A. Schulman ◽  
Gary H. Lyman
Keyword(s):  
Breast Cancer ◽  
Decision Making ◽  
Estrogen Receptor ◽  
Cost Effectiveness ◽  
Recurrence Score ◽  
Risk Groups ◽  
The United States ◽  
Node Negative ◽  
Estrogen Receptor Positive ◽  
Positive Breast Cancer

1525 Background: The objective of this study was to incorporate evidence from two recently-published studies to reevaluate the cost-effectiveness of the 21-gene Recurrence Score (RS) assay (Oncotype DX) in the context of multifactorial decision making to guide the use of chemotherapy for node-negative, estrogen receptor–positive breast cancer in the United States from the societal and healthcare system perspectives. Methods: We developed a decision-analytic model to first cross-classify hypothetical patients by clinicopathologic characteristics according to the Adjuvant! using risk groups and RS risk groups. We generated estimates of long-term costs, survival, and quality-adjusted survival for the RS-guided and non–RS-guided strategies using a probabilistic state transition model. In addition to costs for the 21-gene assay, we assigned attributable costs for chemotherapy, hormonal therapy, monitoring for disease recurrence, and distant recurrence. For the societal perspective, we also considered incremental patient time costs. Costs and survival were discounted at 3% annually. Results: With the RS-guided strategy, 40.4% of patients were expected to receive chemotherapy relative to 47.3% in the non–RS-guided strategy. Targeted use of chemotherapy in the RS-guided strategy was expected to increase survival by 0.19 years (95% CI, 0.09 to 0.32) and 0.16 QALYs (95% CI, 0.08 to 0.28). Lifetime direct medical costs were expected to be $2692 (95% CI, 1546 to 3821) higher with the RS-guided strategy. The incremental cost-effectiveness ratios (ICERs) were $14,059 per life-year saved (95% CI, $6840-$28,912) and $16,677 per QALY (95% CI, $7613-$37,219). When incorporating lower indirect costs of $950 per patient, the ICERs were $9095 per life-year saved (95% CI, dominant-$23,397) and $10,788 per QALY (95% CI, $6840-$30,265). In probabilistic sensitivity analysis, more than 99% of the ICERs were less than $50,000 per life-year saved and per QALY. Conclusions: Our updated cost-effectiveness estimates are supportive of the economic value of the 21-gene RS assay in the setting of node-negative, estrogen receptor–positive breast cancer.

21-gene recurrence score testing in the older population with estrogen receptor-positive breast cancer

2019 ◽  
Vol 10 (2) ◽  
pp. 322-329 ◽  
Author(s):  
Scott Kizy ◽  
Ariella M. Altman ◽  
Schelomo Marmor ◽  
Jason W. Denbo ◽  
Eric H. Jensen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Recurrence Score ◽  
Older Population ◽  
Estrogen Receptor Positive ◽  
Positive Breast Cancer
Sign in / Sign up

Export Citation Format

Share Document